A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome

Fertility and Sterility

Volumn 67, Issue 3, 1997, Pages 463-468

  Genazzani, Alessandro D ^a   Petraglia, Felice ^a   Battaglia, Cesare ^a   Gamba, Ombretta ^a   Volpe, Annibale ^a   Genazzani, Andrea R ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Ferriman Gallwey score; GnRH agonist; hypothalamus pituitary gonadal axis; oral contraceptive; ovulation; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; HYDROXYPROGESTERONE; LEUPRORELIN; LOW DOSE ORAL CONTRACEPTIVE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; SEX HORMONE;

ACNE; ANOVULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM CARE; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031029834     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)80070-2     Document Type: Article

References (22)

1. Insler V. Lunenfeld B. Polycystic ovarian disease: a challenge and controversy. Gynecol Endocrinol 1990;4:51-69.
2. Ehrmann DA. Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-53.
3. Dahlgren E. Janson PO. Polycystic ovary syndrome: longterm metabolic consequences. Int J Gynaecol Obstet 1994;44:3-8.
4. Genazzani AD, Petraglia F, Pianazzi F, Volpogni C, Genazzani AR. The concomitant release of andrnstencdione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 1993;7:33-41.
5. Schoemaker J. Neuroendocrine control in polycystic ovary-like syndrome. Gynecol Endocrinol 1991;5:277-88.
6. Miller JE, Bray MA, Faiman C, Reyes FI. Characterization of 24-h cortisol release in obese and non-obese hyperandrogenic women. Gynecol Endocrinol 1994;8:247-54.
7. Cullberg G, Hamberger L. Mattson LA, Mobacken H, Samsioe G. Effects of a low-dose desogestrel-ethinyl estradiol combination on hirsutism, androgens and sex hormone binding globulin in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 1985;6:195-202.
8. Pucci E, Genazzani AD, Monzani F, Lippi F, Angelini F, Gargani M, et al. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol 1995;9:221-8.
9. Ciotta L, Cianci A, Calogero AE, Palumbo MA, Marietta E, Sciuto A, et al. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995;64:299-306.
10. Ciotta L, Cianci A, Giuffrida G, Marietta E, Aglianò A, Palumbo G. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil Steril 1996;65:61-7.
11. Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994;61:817-22.
12. Heiner JS, Greendale GA, Kawakami AK, Lapolt PS, Fisher M, Young D, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995;80:3412-8.
13. Speroff L, Glass RH, Kase NG. Steroid contraception. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. Baltimore: Williams & Wilkins, 1989:461-98.
14. Can- BR, Breslau NA. Givens C, Byrd W, Barnett-Hamm C. Marshburn PB. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995;80:1169-78.
15. Genazzani AD, Petraglia F. Fabbri G, Monzani A, Montanini V, Genazzani AR. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril 1990;54:222-6.
16. Genazzani AD, Petraglia F, Benatti R, Montanini V, Algeri I, Volpe A, et al. Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab 1991;72:1220-5.
17. Adashi EY. Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism. Fertil Steril 1990;53:765-79.
18. Lemay A, Surrey ES, Friedman AJ. Extending the use of gonadotropin-releasing hormone agonists: the emerging role of steroidal and nonsteroidal agents. Fertil Steril 1994;61:21-34.
19. Azziz R. Ochoa TM, Bradley EL, Dowing Potter H, Boots LR. Leuprolide and estrogens versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab 1995;80:3406-11.
20. Genazzani AD, Petraglia F, Gastaldi M, Volpogni C, Gamba O, Massolo F, et al. Evidence suggesting an additional control mechanism regulating episodic secretion of luteinizing hormone and follicle stimulating hormone in prepubertal children and post-menopausal women. Hum Reprod 1994;9:1807-12.
21. Genazzani AD, Massolo F, Ferrari E, Gandolfi A, Petraglia F, Genazzani AR. Long-term GnRH agonist administration revealed a GnRH independent mechanism stimulating FSH discharge in humans. Eur J Endocrinol 1996;134:77-83.
22. McNatty KP, Smith DM, Makris A, DeGrazia C. The intraovarian sites of androgen and estrogen formation in women with normal and hyperandrogenic ovaries as judged by in vitro experiments. J Clin Endocrinol Metab 1980;50:755-63.